Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Lung Neoplasms 5Neoplasms 4Neoplasm Metastasis 4Hematologic Neoplasms 3Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Lymphoma, Large-Cell, Anaplastic 2Breast Neoplasms 2Brain Neoplasms 2Thyroid Neoplasms 1Sexual Dysfunction, Physiological 1Sarcoma 1Rare Tumour 1Rare Tumor 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Lymphoma 1Glioblastoma 1Genomic Instability 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Disease Resistance 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 7Doxorubicin 4Cyclophosphamide 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cisplatin 3regorafenib 2Vincristine 2Tranexamic Acid 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Radiation 2Proton Therapy 2Nivolumab 2Methotrexate 2Methods 2Interviews as Topic 2Indocyanine Green 2Everolimus 2Curettage 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tocilizumab 1samarium Sm-153 lexidronam 1poly ICLC 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bone Neoplasms × alectinib × Clear all
NCT07560410 2026-05-11

Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

China Medical University Hospital

Phase 1/2 Not yet recruiting
10 enrolled
Sarcoma

Bone Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡